| Literature DB >> 27893425 |
Xiang Ma1, Chi Huang1, Dakui Luo1, Younan Wang1, Ran Tang1, Xiangkun Huan1, Yi Zhu2, Zekuan Xu1, Ping Liu3, Li Yang1.
Abstract
Tissue differentiation-inducing non-protein coding RNA (TINCR) is required for normal epidermal differentiation. TINCR is also strongly overexpressed in human gastric cancer (GC) and contributes to carcinogenesis and tumor progression. However, the association between TINCR polymorphisms and the risk of any diseases, such as GC, remains unknown. In the present study, the tag single nucleotide polymorphisms rs8113645, rs2288947, rs8105637, and rs12610531 were analyzed in 602 patients with GC and 602 age- and sex-matched controls. Polymorphisms were genotyped using TaqMan technology. Carriers of variant rs8113645 and rs2288947 alleles indicated reduced risks of GC (p = 0.003 and 0.037, respectively). A allele genotypes of rs8113645 and G allele genotypes of rs2288947 (rs8113645 GA and AA; rs2288947 AG and GG) were also significantly associated with decreased GC risk (p < 0.05). Stratification analysis displayed that the correlations between GC risk and variant genotypes of both rs8113645 and rs2288947were more evident in younger individuals, men, nonsmokers, and individuals from rural areas. We also demonstrated that rs8113645 GA+AA genotype carriers had lower TINCR mRNA expression levels compared with common genotype in both normal and GC tissues (p < 0.05). These results suggest that long non-coding RNA TINCR polymorphisms may be implicated in GC development.Entities:
Keywords: TINCR; gastric cancer; genotype; polymorphism
Mesh:
Substances:
Year: 2016 PMID: 27893425 PMCID: PMC5349975 DOI: 10.18632/oncotarget.13513
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Demographic information
| Characteristics | Cases (n = 602) | Controls (n = 602) | |
|---|---|---|---|
| Age (y)* | 60.6±10.7 | 59.5±12.9 | 0.087 |
| Gender, (n (%)) | |||
| Male | 438 (72.8) | 409 (67.9) | 0.067 |
| Hypertension, (n (%)) | |||
| Yes | 172 (28.6) | 181 (30.1) | 0.569 |
| Yes | 61(10.1) | 76(12.6) | 0.173 |
| Smoking, (n (%)) | |||
| Smokers | 128(21.3) | 94 (15.6) | |
| Residence, (n (%)) | |||
| Urban | 244 (47.4) | 271 (52.0) | 0.116 |
| Tumor differentiation (n (%)) | |||
| Depth of tumor infiltration (n (%)) | |||
| Lymph node metastasis (n (%)) | |||
| Localization (n (%)) | |||
| Noncardia | 336(55.8) | ||
* Median (25th-75th percentiles).
Association between TINCR gene polymorphisms and risk of gastric cancer
| genotype | Cases N (%) | Controls N (%) | Crude ORa (95% CIb) | Adjusted OR (95% CI)* | ||
|---|---|---|---|---|---|---|
| rs8113645 | ||||||
| GA | 121 (20.1) | 150(24.9) | ||||
| AA | 8 (1.3) | 18(3.0) | ||||
| GA + AA | 129 (21.4) | 168(27.9) | ||||
| rs2288947 | ||||||
| AG | 227 (37.7) | 257 (42.7) | ||||
| GG | 52 (8.6) | 68 (11.3) | ||||
| AG + GG | 279(46.3) | 325 (54.0) | ||||
| rs12610531 | ||||||
| AG | 305 (50.7) | 318(52.8) | 0.93 (0.71-1.22) | 0.594 | 0.93 (0.71-1.23) | 0.621 |
| GG | 142 (23.5) | 134(22.3) | 1.02(0.74-1.41) | 0.913 | 1.01(0.73-1.41) | 0.947 |
| AG + GG | 446 (74.2) | 452(75.1) | 0.96 (0.74-1.24) | 0.728 | 0.96 (0.74-1.24) | 0.735 |
| rs8105637 | ||||||
| AG | 259 (43.0) | 247 (41.0) | 1.09 (0.86-1.38) | 0.486 | 1.07 (0.84-1.36) | 0.591 |
| AA | 50 (8.3) | 51 (8.5) | 1.02(0.67-1.55) | 0.937 | 1.05(0.68-1.61) | 0.831 |
| AG + GG | 339 (51.3) | 298 (49.5) | 1.08 (0.86-1.35) | 0.526 | 1.06 (0.84-1.34) | 0.609 |
| HWE | 0.493 | 0.934 | ||||
Abbreviations: *Adjusted for age, sex, smoking status, residence, hypertension, and diabetes.
aOR, odds ratio;
bCI, confidence interval
cHWE, Hardy–Weinberg expectations
Figure 1Correlation between rs8113645 and rs2288947 genotypes and expression of TINCR mRNA
A. Genotype-phenotype correlation for rs8113645 and relative expression levels of TINCR mRNA. Relative TINCR mRNA expression levels were significantly lower for the GA (0.011 ± 0.004) and GA+AA genotypes (0.009 ± 0.003) than the GG genotype (0.124 ± 0.003) in normal tissues (*P < 0.05; **P < 0.01). In gastric cancer tissues, relative TINCR mRNA expression levels were significantly lower for the GA (0.147 ± 0.0049), AA (0.031 ± 0.016) and GA+AA genotypes (0.121 ± 0.039) than the GG genotype (0.314 ± 0.039) (*P < 0.05; **P < 0.01). B. Genotype-phenotype correlation for rs2288947 and relative expression levels of TINCR mRNA. Relative TINCR mRNA expression levels were similar among the three groups with rs2288947 AA, AG and GG genotypes in both normal and gastric cancer tissues.
Stratified analyses for TINCR genotypes in cases and controls
| Variable | n GA+AA (%)/n GG (%) for rs8113645 | Allelic odds ratios and 95% confidence intervals for rs8113645 | n AG+GG (%)/ n AA (%) for rs2288947 | Allelic odds ratios and 95% confidence intervals for rs2288947 | ||||
|---|---|---|---|---|---|---|---|---|
| Cases | Controls | Adjusted OR | Cases | Controls | Adjusted OR | |||
| 72(12.0)/247(41.0) | 75(12.5)/206(34.2) | 0.77 (0.52-1.12) | 0.172 | 151(25.1)/168(27.9) | 152(25.2)/129(21.4) | 0.74 (0.53-1.03) | 0.075 | |
| 58(9.60)/225(37.4) | 93(15.4)/228(37.9) | 128(21,3)/l 55(25.7) | 173(28.7)/148(24.6) | |||||
| 43(7.10)/121(20.1) | 46(7.6)/147(24.4) | 1.17(0.72-1.90) | 0.532 | 92(15.3)/72(12.0) | 91(15.1)/ 73(12.1) | 1.39(0.91-2.12) | 0.133 | |
| 87(14.5)/351(58.3) | 122(20.3)/287(47.7) | 0.001 | 187(31.1)/251(41.7) | 234(38.9)/204(33.9) | ||||
| 26(4.3)/102(16.9) | 27(4.5)/67(11.1) | 0.63 (0.33-1.20) | 0.161 | 60(10.0)/68(11.3) | 64(10.6)/64(10.6) | 0.65 (0.38-1.13) | 0.129 | |
| 104(17.3)/370(61.5) | 141(23.4)/367(61.0) | 219(36.4)/255(42.4) | 261(43.4)/213(35.4) | |||||
| 75(12.5)/283(47.0) | 94(15.6)/237(39.4) | 164(27.2)/194(32.2) | 192(31.9)/166(27.6) | |||||
| 55(9.1)/189(31.4) | 74(12.3)/197(32.7) | 0.78 (0.52-1.17) | 0.229 | 115(19.1)/129(21.4) | 133(22.1)/l 11(18.4) | 0.75 (0.53-1.07) | 0.111 | |
* Adjusted for age, sex, smoking status, residence, hypertension, and diabetes.
Associations between variant TINCR genotypes and clinicopathologic characteristics of gastric cancer
| Variable | GA+AA, GG for rs8113645 | Allelic odds ratios and 95% confidence intervals for rs8113645 | AG+GG, AA for rs2288947 | Allelic odds ratios and 95% confidence intervals for rs2288947 | ||||
|---|---|---|---|---|---|---|---|---|
| CT+TT, n | CC, n | Adjusted OR(95%CI)* | AG+GG, n | AA, n | Adjusted OR (95% CI)* | |||
| Tumor differentiation | ||||||||
| Moderate | 30 | 103 | 0.93 (0.29-2.92) | 0.896 | 64 | 69 | 0.90 (0.35-2.30) | 0.825 |
| Poor | 95 | 351 | 1.01 (0.36-2.83) | 0.982 | 204 | 242 | 0.97 (0.41-2.29) | 0.943 |
| Depth of tumor infiltration | ||||||||
| T2 | 11 | 57 | 0.87(0.37-2.07) | 0.752 | 34 | 34 | 1.12(0.57-2.22) | 0.746 |
| T3 | 69 | 200 | 1.43 (0.79-2.58) | 0.240 | 118 | 151 | 0.86 (0.53-1.40) | 0.547 |
| T4 | 32 | 143 | 0.90 (0.46-1.76) | 0.750 | 84 | 91 | 1.03 (0.61-1.75) | 0.905 |
| Lymph node metastasis | ||||||||
| Positive | 84 | 322 | 0.85 (0.56-1.28) | 0.431 | 184 | 222 | 0.87(0.62-1.23) | 0.428 |
| Localization | ||||||||
| Noncardia | 78 | 258 | 1.22(0.82-1.82) | 0.327 | 167 | 169 | 1.32 (0.95-1.84) | 0.094 |
* Adjusted for age, sex, smoking status, residence, hypertension, and diabetes.